Dapagliflozin

CAS Number: 461432-26-8

Molecular Formula: C21H25ClO6

Purity: Dapagliflozin 98% purity

About Dapagliflozin

Dapagliflozin API (CAS 461432-26-8) is a sodium-glucose co-transporter 2 (SGLT2) inhibitor and an orally active antidiabetic API supplied in oral solid dosage grade. It was the first SGLT2 inhibitor approved in its class. Dapagliflozin API is formulated into oral tablets that improve glycemic control in adults with typ...

Synonyms

(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6- (hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol
BMS 512148
BMS-512148
BMS512148

View all

Dapagliflozin Specifications

CAS Number

461432-26-8

Molecular Formula

C21H25ClO6

Molecular Weight

408.87 g/mol

IUPAC Name

(2S,3R,4R,5S,6R)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol

PubChem CID

9887712

HSN No

30049099

CAS Number

461432-26-8

Molecular Formula

C21H25ClO6

Molecular Weight

408.87 g/mol

IUPAC Name

(2S,3R,4R,5S,6R)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol

PubChem CID

9887712

HSN No

30049099

Molecular Weight

408.87 g/mol

Purity

Dapagliflozin 98% purity

Antidiabetic Agent

A selective sodium-glucose cotransporter 2 (SGLT2) inhibitor used as an adjunct to diet and exercise to improve glycemic control in adults and children 10 years and older with type 2 diabetes mellitus

Cardiovascular Therapeutic

A prescription medication indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure or type 2 diabetes

Chronic Kidney Disease Treatment

A therapeutic agent utilized to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in patients with chronic kidney disease

SGLT2 Inhibitor

A potent and selective renal sodium-dependent glucose cotransporter 2 inhibitor used in biochemical research and pharmaceutical development to study glucose reabsorption and urinary glucose excretion.

(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6- (hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol
BMS 512148
BMS-512148
BMS512148